BioCardia, Inc. income statement BCDA

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, BioCardia, Inc. reported revenue of $0, down 100.0% from the year before. It recorded a net loss of $8.2 million. Across the 9 fiscal years shown, revenue shrank from $576,000 in fiscal 2016 to $58,000 in fiscal 2024, about 24.9% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	0 -100.0%	0 -87.8%	0 -64.7%	1 +33.2%	1 +600.0%	0 -79.6%	1 +13.6%	1 +30.5%	0 -16.8%	1
Cost of revenue	—	—	—	—	0 -100.0%	0 -98.9%	0 -30.8%	1 -25.1%	1 -7.5%	1
Gross profit	—	—	—	—	1 +619.9%	0 -59.9%	0 +225.9%	0 +151.2%	-0 -24.1%	-0
Research and development	5 +13.1%	4 -43.2%	8 -12.5%	9 +3.2%	9 -12.8%	10 +14.6%	9 +1.3%	8 +45.8%	6 +74.1%	3
Selling, general and administrative	3 -9.7%	4 -16.5%	4 -0.5%	4 -13.1%	5 -13.2%	6 -2.4%	6 +4.3%	6 -10.0%	6 +55.7%	4 +1974.7%
Operating income	-8 -3.5%	-8 +31.3%	-12 +2.2%	-12 +5.8%	-13 +18.7%	-16 -9.3%	-14 -0.8%	-14 -13.7%	-12 -63.1%	-8 -40.7%
Income tax	0	0	0	0	0	0	0	0	0	0
Net income	-8 -3.5%	-8 +31.3%	-12 +2.8%	-12 +5.7%	-13 +15.9%	-15 -2.0%	-15 -5.2%	-14 -13.6%	-12 -19.4%	-10 -53.9%
Basic EPS	-1.23 +57.6%	-2.90 +64.6%	-8.19 -1122.4%	-0.67	—	—	—	—	—	—
Weighted average shares, basic	7 +143.0%	3 +94.3%	1 -92.0%	18	—	—	—	—	—	—
Other measures
Depreciation and amortization	0 -64.2%	0 -20.2%	0 +2.4%	0 +36.7%	0 -11.8%	0 -38.7%	0 +26.1%	0 +12.8%	0 +100.0%	0
EBITDA	-8 -4.0%	-8 +31.4%	-12 +2.2%	-12 +6.0%	-13 +18.7%	-15 -9.6%	-14 -0.6%	-14 -13.7%	-12 -62.9%	-8
Interest coverage	—	—	—	—	—	-5,176.33x	-126.90x	-8.12x	—	—
Margins
Gross margin	—	—	—	—	100.00%	97.24%	49.58%	17.28%	-44.05%	-29.51%
Operating margin	—	-13,794.83%	-2,441.09%	-880.25%	-1,244.33%	-10,709.66%	-2,001.83%	-2,256.32%	-2,589.77%	-1,320.83%
Profit margin	—	-13,700.00%	-2,425.79%	-880.70%	-1,243.65%	-10,347.59%	-2,071.69%	-2,237.92%	-2,569.52%	-1,789.93%
EBITDA margin	—	-13,679.31%	-2,423.48%	-874.19%	-1,238.42%	-10,662.76%	-1,986.20%	-2,242.24%	-2,573.49%	-1,314.06%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: BCDA (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Sunnyvale, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 925741
Former names: Tiger X Medical, Inc. (until Oct 17, 2016); Cardo Medical, Inc. (until May 25, 2011); CLICKNSETTLE COM INC (until Oct 20, 2008); NAM CORP (until Mar 29, 2000)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.